featured
ESMO 2020: Addition of Nivolumab to Chemotherapy Improves Outcomes in Patients With Advanced Gastric/Esophageal/Gastroesophageal Junction Cancer
Authors suggest it could become standard of care, but expert requests more data
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.